{"id":"https://openalex.org/W2257499491","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5505","title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).","display_name":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).","publication_year":2013,"publication_date":"2013-05-20","ids":{"openalex":"https://openalex.org/W2257499491","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5505","mag":"2257499491"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2013.31.15_suppl.5505","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5505","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.5505","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079383798","display_name":"Jonathan Andrew Ledermann","orcid":"https://orcid.org/0000-0003-3799-3539","observed_orcids":["https://orcid.org/0000-0003-3799-3539"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jonathan A. Ledermann","raw_affiliation_strings":["University College London Cancer Institute, University College London Cancer Hospital, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London Cancer Institute, University College London Cancer Hospital, London, United Kingdom","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078567055","display_name":"Philipp Harter","orcid":"https://orcid.org/0000-0002-9663-5005","observed_orcids":["https://orcid.org/0000-0002-9663-5005"]},"institutions":[{"id":"https://openalex.org/I4210146447","display_name":"Kliniken Essen-Mitte","ror":"https://ror.org/03v958f45","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210146447"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Philipp Harter","raw_affiliation_strings":["Kliniken Essen Mitte, Essen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kliniken Essen Mitte, Essen, Germany","institution_ids":["https://openalex.org/I4210146447"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009351129","display_name":"Charlie Gourley","orcid":"https://orcid.org/0000-0002-2377-7221","observed_orcids":["https://orcid.org/0000-0002-2377-7221"]},"institutions":[{"id":"https://openalex.org/I2802581871","display_name":"Edinburgh Cancer Research","ror":"https://ror.org/05a7t9b67","country_code":"GB","type":"facility","lineage":["https://openalex.org/I2801316944","https://openalex.org/I2802581871","https://openalex.org/I98677209"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Charlie Gourley","raw_affiliation_strings":["Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom","institution_ids":["https://openalex.org/I2802581871"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021894535","display_name":"Michael Leonard Friedlander","orcid":"https://orcid.org/0000-0003-3090-795X","observed_orcids":["https://orcid.org/0000-0003-3090-795X"]},"institutions":[{"id":"https://openalex.org/I4210108821","display_name":"Prince of Wales Hospital","ror":"https://ror.org/022arq532","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210108821"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Michael Friedlander","raw_affiliation_strings":["Prince of Wales Hospital, Sydney, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Prince of Wales Hospital, Sydney, Australia","institution_ids":["https://openalex.org/I4210108821"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058535647","display_name":"Ignace B. Vergote","orcid":"https://orcid.org/0000-0002-7589-8981","observed_orcids":["https://orcid.org/0000-0002-7589-8981"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Ignace Vergote","raw_affiliation_strings":["UZ Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UZ Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047753094","display_name":"Gordon J.S. Rustin","orcid":"https://orcid.org/0000-0002-2749-5467","observed_orcids":["https://orcid.org/0000-0002-2749-5467"]},"institutions":[{"id":"https://openalex.org/I2801038905","display_name":"Mount Vernon Hospital","ror":"https://ror.org/04am5a125","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799786270","https://openalex.org/I2801038905"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gordon J. S. Rustin","raw_affiliation_strings":["Mount Vernon Hospital, Middlesex, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mount Vernon Hospital, Middlesex, United Kingdom","institution_ids":["https://openalex.org/I2801038905"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085126287","display_name":"Clare L. Scott","orcid":"https://orcid.org/0000-0002-3689-5956","observed_orcids":["https://orcid.org/0000-0002-3689-5956"]},"institutions":[{"id":"https://openalex.org/I1320473756","display_name":"The Royal Melbourne Hospital","ror":"https://ror.org/005bvs909","country_code":"AU","type":"funder","lineage":["https://openalex.org/I1320473756","https://openalex.org/I4210158168"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Clare L. Scott","raw_affiliation_strings":["Royal Melbourne Hospital, Victoria, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Royal Melbourne Hospital, Victoria, Australia","institution_ids":["https://openalex.org/I1320473756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084392138","display_name":"Werner Meier","orcid":"https://orcid.org/0000-0003-2508-5410","observed_orcids":["https://orcid.org/0000-0003-2508-5410"]},"institutions":[{"id":"https://openalex.org/I4210124232","display_name":"Evangelisches Krankenhaus D\u00fcsseldorf","ror":"https://ror.org/036j3hh72","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210124232"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Werner Meier","raw_affiliation_strings":["Evangelical Hospital, D\u00fcsseldorf, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Evangelical Hospital, D\u00fcsseldorf, Germany","institution_ids":["https://openalex.org/I4210124232"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058238015","display_name":"Ronnie Shapira\u2010Frommer","orcid":"https://orcid.org/0000-0001-6170-080X","observed_orcids":["https://orcid.org/0000-0001-6170-080X"]},"institutions":[{"id":"https://openalex.org/I16391192","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49","country_code":"IL","type":"education","lineage":["https://openalex.org/I16391192"]},{"id":"https://openalex.org/I2799810450","display_name":"Sheba Medical Center","ror":"https://ror.org/020rzx487","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799810450"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Ronnie Shapira-Frommer","raw_affiliation_strings":["Ella Institute for Research and Treatment of Melanoma, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine Tel Aviv University, Tel Hashomer, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ella Institute for Research and Treatment of Melanoma, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine Tel Aviv University, Tel Hashomer, Israel","institution_ids":["https://openalex.org/I16391192","https://openalex.org/I2799810450"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039578268","display_name":"Tamar Safra","orcid":"https://orcid.org/0000-0001-6910-6426","observed_orcids":["https://orcid.org/0000-0001-6910-6426"]},"institutions":[{"id":"https://openalex.org/I2799807261","display_name":"Tel Aviv Sourasky Medical Center","ror":"https://ror.org/04nd58p63","country_code":"IL","type":"healthcare","lineage":["https://openalex.org/I2799807261"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Tamar Safra","raw_affiliation_strings":["Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","institution_ids":["https://openalex.org/I2799807261"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067743297","display_name":"Daniela Elena Matei","orcid":"https://orcid.org/0000-0003-2169-5035","observed_orcids":["https://orcid.org/0000-0003-2169-5035"]},"institutions":[{"id":"https://openalex.org/I4394709130","display_name":"Indiana University School of Medicine","ror":"https://ror.org/02ets8c94","country_code":"US","type":"education","lineage":["https://openalex.org/I4394709130","https://openalex.org/I592451"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniela Matei","raw_affiliation_strings":["Indiana University School of Medicine, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Indiana University School of Medicine, Indianapolis, IN","institution_ids":["https://openalex.org/I4394709130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064212341","display_name":"Anitra Fielding","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anitra Fielding","raw_affiliation_strings":["AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088414766","display_name":"Euan Macpherson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Euan Macpherson","raw_affiliation_strings":["AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087646089","display_name":"Brian Andrew Dougherty","orcid":"https://orcid.org/0000-0002-0093-1142","observed_orcids":["https://orcid.org/0000-0002-0093-1142"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Dougherty","raw_affiliation_strings":["AstraZeneca, Waltham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Waltham, MA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087689900","display_name":"Juliane Margarete J\u00fcrgensmeier","orcid":"https://orcid.org/0000-0001-8438-2429","observed_orcids":["https://orcid.org/0000-0001-8438-2429"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Juliane M. J\u00fcrgensmeier","raw_affiliation_strings":["AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111925004","display_name":"Maria C. M. Orr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Maria Orr","raw_affiliation_strings":["AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058249824","display_name":"Ursula A. Matulonis","orcid":"https://orcid.org/0000-0002-3103-6992","observed_orcids":["https://orcid.org/0000-0002-3103-6992"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ursula Matulonis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":15,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":40,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"15_suppl","first_page":"5505","last_page":"5505"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.7979999780654907},{"id":"https://openalex.org/keywords/serous-ovarian-cancer","display_name":"serous ovarian cancer","score":0.8659999966621399},{"id":"https://openalex.org/keywords/platinum-sensitive-recurrent-ovarian-cancer","display_name":"platinum-sensitive recurrent ovarian cancer","score":0.8080000281333923},{"id":"https://openalex.org/keywords/brca-mutations","display_name":"BRCA mutations","score":0.9120000004768372},{"id":"https://openalex.org/keywords/germline-brca-mutation","display_name":"germline BRCA mutation","score":0.9629999995231628},{"id":"https://openalex.org/keywords/somatic-brca-mutations","display_name":"somatic BRCA mutations","score":0.9950000047683716},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9449999928474426},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9829999804496765},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9750000238418579},{"id":"https://openalex.org/keywords/trial-outcome-index","display_name":"Trial Outcome Index","score":0.5950000286102295},{"id":"https://openalex.org/keywords/subgroup-analysis","display_name":"subgroup analysis","score":0.5720000267028809},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.42100000381469727},{"id":"https://openalex.org/keywords/platinum-resistance","display_name":"platinum resistance","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8971617221832275},{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.8351224660873413},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6677374243736267},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.5478038191795349},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.537577211856842},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4589546322822571},{"id":"https://openalex.org/C2780194787","wikidata":"https://www.wikidata.org/wiki/Q4836333","display_name":"BRCA mutation","level":4,"score":0.44954273104667664},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4049019515514374},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3811689615249634},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2013.31.15_suppl.5505","doi":"https://doi.org/10.1200/jco.2013.31.15_suppl.5505","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2013.31.15_suppl.5505","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2130078242","https://openalex.org/W2088376108","https://openalex.org/W4408519118","https://openalex.org/W4205422786","https://openalex.org/W1996017104","https://openalex.org/W2530008699","https://openalex.org/W4362677814","https://openalex.org/W2335929230","https://openalex.org/W2752757943","https://openalex.org/W3029554970"],"abstract_inverted_index":{"5505":[0],"Background:":[1],"Previously,":[2],"we":[3],"reported":[4],"that":[5,49],"maintenance":[6,161,328],"treatment":[7,329],"with":[8,28,63,86,159,183,244,338],"the":[9,155,232,255,276,323,332],"oral":[10],"PARP":[11,273],"inhibitor":[12],"olaparib":[13,50,160,228,311],"(400":[14],"mg":[15],"bid)":[16],"led":[17,235,330],"to":[18,53,236,331],"a":[19,54,64,148,177,225,237,271,339],"significant":[20,178],"PFS":[21,157,196],"improvement":[22],"vs":[23,162,166,207,229,248,304],"placebo":[24,163,230,268],"in":[25,61,231,279,293,319,336,346],"patients":[26],"(pts)":[27],"platinum-sensitive":[29],"relapsed":[30],"SOC":[31],"(Ledermann":[32],"et":[33],"al":[34],"NEJM2012).":[35],"A":[36],"preplanned":[37],"subgroup":[38],"analysis":[39,220,283],"from":[40,111,254],"this":[41,280],"randomized,":[42],"double-blind":[43],"Phase":[44],"II":[45],"trial":[46,351],"(NCT00753545)":[47],"suggested":[48],"may":[51,74],"lead":[52],"greater":[55],"PFS,":[56],"and":[57,123,176,257,263,291,322],"an":[58,218,294],"OS,":[59],"benefit":[60,158,197,335],"pts":[62,73,85,97,138,146,153,202,269,287,308,321,337],"known":[65,135],"germline":[66],"BRCAm":[67,125,149,286,320],"(gBRCAm).":[68],"Since":[69],"gBRCA":[70,132],"wild-type":[71],"(gBRCAwt)":[72],"develop":[75],"somatic":[76],"tumor":[77,113],"(t)BRCAm,":[78],"efficacy":[79],"analyses":[80],"were":[81,203,260],"performed":[82],"for":[83,94,136,312],"all":[84,95,285],"BRCAm.":[87,340],"Methods:":[88],"gBRCAm":[89,122,152,256,267],"status":[90,108,133],"was":[91,109,134,198,288,317],"determined":[92,110],"retrospectively":[93],"consenting":[96],"(n":[98],"=":[99,193],"166)":[100],"using":[101],"blood":[102],"samples":[103,114],"taken":[104],"before":[105],"randomization.":[106],"tBRCAm":[107,201],"archival":[112],"of":[115,221,227,239,246,284,297],"196":[116],"pts.":[117],"We":[118],"analyzed":[119],"PFS/OS":[120],"by":[121],"total":[124],"status.":[126],"Preliminary":[127],"data":[128,278,343],"are":[129],"reported.":[130],"Results:":[131],"218/265":[137],"(gBRCAm,":[139],"96;":[140],"gBRCAwt,":[141],"122).":[142],"Including":[143],"tBRCAm,":[144],"136":[145],"had":[147,154],"(BRCAwt,":[150],"116).":[151],"greatest":[156,333],"(median:":[164,205],"11.2":[165,206],"4.1":[167],"months":[168],"[m];":[169],"HR,":[170,210],"0.17;":[171],"95%":[172,189,212],"CI":[173,190,213,242,300],"0.09-0.32;":[174],"P<0.001)":[175],"QoL":[179],"improvement,":[180],"as":[181],"measured":[182],"Trial":[184],"Outcome":[185],"Index":[186],"(OR,":[187],"4.08;":[188],"1.11-19.85;":[191],"p":[192,215],"0.03).":[194],"The":[195,282],"consistent":[199],"when":[200],"included":[204],"4.3":[208],"m;":[209],"0.19;":[211],"0.11-0.32;":[214],"<0.0001).":[216],"In":[217],"interim":[219],"OS":[222,277,295],"(58%":[223],"maturity),":[224],"comparison":[226],"overall":[233,324],"population":[234],"HR":[238,296],"0.88":[240],"(95%":[241,299],"0.64-1.21)":[243],"medians":[245],"29.8":[247],"27.8":[249],"m,":[250],"respectively.":[251],"Although":[252],"HRs":[253],"gBRCAwt":[258],"subgroups":[259],"similar":[261,318],"(0.85":[262],"0.84,":[264],"respectively),":[265],"13/37":[266],"received":[270,310],"subsequent":[272],"inhibitor,":[274],"confounding":[275],"subgroup.":[281],"less":[289],"confounded":[290],"resulted":[292],"0.74":[298],"0.46-1.19;":[301],"median:":[302],"34.9":[303],"31.9":[305],"m).":[306],"19":[307],"have":[309],">3":[313],"years.":[314],"Olaparib":[315,327],"tolerability":[316],"population.":[325],"Conclusions:":[326],"clinical":[334],"These":[341],"compelling":[342],"warrant":[344],"confirmation":[345],"phase":[347],"III":[348],"trials.":[349],"Clinical":[350],"information:":[352],"NCT00753545.":[353]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":21},{"year":2013,"cited_by_count":7}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2016-06-24T00:00:00"}